Core Viewpoint - The report highlights the financial performance and strategic focus of Shandong Huate Dayin Health Co., Ltd., particularly in the children's pharmaceutical sector, emphasizing its commitment to innovation and market leadership in children's health products [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 was approximately 1.17 billion yuan, representing a 1.39% increase compared to the same period last year [2]. - The net profit attributable to shareholders was around 337.47 million yuan, showing a 1.69% increase year-on-year [2]. - The net cash flow from operating activities significantly rose by 61.44% to approximately 674.61 million yuan [2]. - The total assets at the end of the reporting period were approximately 4.60 billion yuan, a decrease of 6.78% from the previous year [2]. Business Overview - The company operates primarily in the pharmaceutical manufacturing industry, focusing on children's health products, with a significant portion of revenue generated from its subsidiary, Dayin Pharmaceutical, which achieved 1.15 billion yuan in revenue, accounting for 98.59% of the company's total revenue [2][3]. - Dayin Pharmaceutical is recognized as a pioneer in the children's pharmaceutical sector, with a product portfolio that includes various children's medications and nutritional products [3][5]. Market Environment - The pharmaceutical industry is facing challenges, with a reported 2.3% decline in drug sales across public hospitals and retail pharmacies in the first quarter of 2025 [2][3]. - Government policies aimed at encouraging childbirth and improving children's healthcare are expected to create growth opportunities in the children's health market [3][5]. R&D and Innovation - The company emphasizes a tailored approach to children's medications, supported by its own research and development center and collaborations with academic institutions [5][9]. - The company has introduced new products, including a registration for sodium valproate oral solution and clinical trial approval for ipratropium bromide aerosol, enhancing its product offerings [7][9]. Competitive Advantage - Dayin Pharmaceutical has established a strong brand presence, with its flagship product, "Yike Xin" (Vitamin AD drops), maintaining a leading market share in its category [10][11]. - The company focuses on high-quality product development, ensuring safety and efficacy tailored to children's needs, which has contributed to its reputation and market position [8][10].

Group 1 - The board of directors of Shandong Huate Dain Health Co., Ltd. held its fourth meeting of the eleventh session on July 2025, chaired by Chairman Zhu Xiaoping, in compliance with relevant laws and regulations [1] - The company's 2025 semi-annual report was reviewed and approved by the audit committee, which confirmed that the report accurately reflects the company's financial status and operating results [1] Group 2 - The company proposed a mid-term profit distribution plan for 2025, which includes a cash dividend of 5 yuan (before tax) for every 10 shares based on a total share capital of 234,331,485 shares as of June 30, 2025 [2] - The profit distribution plan is subject to approval by the company's shareholders' meeting [2] - The company plans to submit several proposals to the shareholders' meeting, including amendments to the articles of association and changes to the business scope [2]

Core Points - The document outlines the rules and procedures for the board meetings of Shandong Huate Dain Health Co., Ltd, ensuring compliance with relevant laws and regulations [1][16] - The board has significant decision-making authority, including long-term development, management appointments, performance evaluations, and major financial matters [2][3] Group 1: Board Authority and Responsibilities - The board is responsible for convening shareholder meetings and reporting on its work [2] - It executes shareholder resolutions and decides on the company's operational plans and investment proposals [2][3] - The board formulates profit distribution plans and strategies for capital increase or decrease [2][3] Group 2: Meeting Procedures - Board meetings are categorized into regular and temporary meetings, with specific notification requirements [5][7] - A quorum for meetings requires the presence of more than half of the directors [8] - Decisions require a majority vote from the attending directors, with specific rules for abstentions and conflicts of interest [11][12] Group 3: Proposal and Voting Process - Proposals must be within the board's authority and accompanied by relevant materials [6][10] - Voting is conducted by a show of hands, and results must be announced promptly [11][12] - If a proposal is not approved, it cannot be reconsidered within a month unless significant changes occur [13][14] Group 4: Documentation and Record Keeping - The board secretary is responsible for recording meeting minutes and maintaining documentation, which must be preserved permanently [28][33] - Meeting resolutions and records require signatures from attending directors, and any dissent must be documented [29][30]

Core Viewpoint - Huatai Dain (000915.SZ) reported a slight increase in revenue and net profit for the first half of 2025, indicating stable performance amidst market conditions [1] Financial Performance - The company achieved operating revenue of 1.17 billion yuan, representing a year-on-year growth of 1.39% [1] - Net profit attributable to shareholders was 337 million yuan, with a year-on-year increase of 1.69% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 332 million yuan, reflecting a year-on-year growth of 4.31% [1] - Basic earnings per share stood at 1.44 yuan [1] Dividend Distribution - The company proposed a cash dividend of 5 yuan (including tax) for every 10 shares to all shareholders [1]

Core Insights - Huate Dain (000915.SZ) reported a revenue of 1.17 billion yuan for the first half of 2025, representing a year-on-year growth of 1.39% [1] - The net profit attributable to shareholders of the listed company was 337 million yuan, an increase of 1.69% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 332 million yuan, reflecting a year-on-year growth of 4.31% [1] - Basic earnings per share stood at 1.44 yuan [1] - The company plans to distribute a cash dividend of 5 yuan (including tax) for every 10 shares to all shareholders [1]

人民财讯8月7日电，华特达因（000915）8月7日晚间发布2025年半年度报告，上半年营业收入11.7亿 元，同比增长1.39%；归母净利润3.37亿元，同比增长1.69%。拟向全体股东每10股派发现金红利5元(含 税)。 ...

山东华特达因健康股份有限公司 章 程 （需经公司股东会审议） 二〇二五年八月八日 第一条 为维护公司、股东、职工和债权人的合法权益， 规范公司的组织和行为，根据《中华人民共和国公司法》（以 下简称《公司法》）、《中华人民共和国证券法》（以下简称 《证券法》）和其他有关规定，制定本章程。 第二条 公司系依照《股份公司规范意见》和其他有关规 定成立的股份有限公司（以下简称"公司"）。 | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 4 | | 第一节 | 股份发行 | 4 | | 第二节 | 股份增减和回购 | 5 | | 第三节 | 股份转让 | 6 | | 第四章 | 股东和股东会 | 7 | | 第一节 | 股东的一般规定 | 7 | | 第二节 | 控股股东和实际控制人 | 11 | | 第三节 | 股东会的一般规定 | 13 | | 第四节 | 股东会的召集 | 15 | | 第五节 | 股东会的提案与通知 | 17 | | 第六节 | 股东会的召开 | 20 | | 第七节 | 股东会的表决和决议 | 23 ...

山东华特达因健康股份有限公司 股东会议事规则 （需经公司股东会审议） 第一章 总则 第一条 为规范山东华特达因健康股份有限公司（以下简称"公司"）行为， 保证股东会依法行使职权，根据《中华人民共和国公司法》（以下简称《公司 法》）《中华人民共和国证券法》（以下简称《证券法》）《上市公司股东会 规则》《山东华特达因健康股份有限公司章程》（以下简称《公司章程》）等 的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、本规则及《公司章程》的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应 当勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会应当在《公司法》和《公司章程》规定的范围内行使职权。 第四条 股东会分为年度股东会和临时股东会。年度股东会每年召开一次， 应当于上一会计年度结束后的6个月内举行。临时股东会不定期召开，出现以下 应当召开临时股东会的情形时，临时股东会应当在2个月内召开： （一）董事人数不足《公司法》规定人数或者《公司章程》所定人数的三 分之二时； （二）公司未弥补的亏损达股本总额三分之一时； （三）单独或者合计持 ...

山东华特达因健康股份有限公司 董事会议事规则 （需经公司股东会审议） 第一条 宗旨 为健全和规范山东华特达因健康股份有限公司（以下简称"公司"或"本公司"） 董事会议事决策程序，保证公司经营、管理工作的顺利进行，根据《中华人民共和国 公司法》、《中华人民共和国证券法》、《上市公司治理准则》等国家有关法律、法 规和《山东华特达因健康股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，并结合本公司的实际情况，制定本规则。 第二条 公司董事会有中长期发展决策权、经理层成员选聘权、经理层成员业绩 考核权、经理层成员薪酬管理权、职工工资分配管理权、重大财务事项管理权等职权。 第三条 董事会对股东会负责，行使以下职权： （一）召集股东会，并向股东会报告工作； （二）执行股东会的决议； （三）决定公司的经营计划和投资方案； （四）制订公司的利润分配方案和弥补亏损方案； （五）制订公司增加或者减少注册资本、发行债券或者其他证券及上市方案； （六）拟订公司重大收购、收购本公司股票或者合并、分立、解散及变更公司形 式的方案； （七）在股东会授权范围内，决定公司对外投资、收购出售资产、资产抵押、对 外担保事项、委托理财、关 ...

证券代码：000915 证券简称：华特达因 公告编号：2025-036 山东华特达因健康股份有限公司 关于修改《公司章程》及变更公司经营范围的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）于 2025 年 8 月 6 日召开第十一届董事会第四次会议，审议通过了"关于修改 《公司章程》及变更公司经营范围的议案"。上述事项尚需提交公司 股东会审议。有关内容公告如下： 一、修改《公司章程》情况 根据修订后的《中华人民共和国公司法》《上市公司章程指引》 《深圳证券交易所股票上市规则》等法律法规、规章规则的相关规定 以及拟变更经营范围的情况，拟对《公司章程》进行修改，修改前后 | 序号 | 修订前章程条款 | 修订后章程条款 | 说明 | | --- | --- | --- | --- | | | 第一条 为维护公司、股东和 | 第一条 为维护公司、股东、 | | | | 债权人的合法权益，规范公司的组 | 职工和债权人的合法权益，规范公 | | | | 织和行为，根据《中华人民共和国 | 司的组织和行为，根据《中 ...